SANDOSTATIN LAR DEPOT

Sandostatin LAR Depot (octreotide acetate) is an octapeptide medication prescribed for the treatment of acromegaly. It is also utilized to alleviate symptoms such as flushing episodes and watery diarrhea caused by carcinoid syndrome or VIP adenomas, which are cancerous tumors.

Dietary changes may be beneficial in addition to Octreotide (Sandostatin®, Sandostatin LAR®). It is recommended to avoid foods that can exacerbate symptoms, including heavy or greasy/fatty, spicy, or acidic foods such as lemons, tomatoes, and oranges. This information is provided by www.oncolink.org and is copyrighted by the Trustees of The University of Pennsylvania in 2022.

You may experience nausea, vomiting, loose/oily stools, constipation, stomach upset, gas, bloating, dizziness, headache, pain, or irritation at the injection site. If any of these symptoms persist or worsen, please notify your doctor or pharmacist immediately.

Quantity: 10
Unit Price: $140.02
Total Price: $1,400.18

If the powder is not fully suspended, continue shaking moderately for an additional 30 seconds. Sandostatin® LAR should only be administered through deep intragluteal injection and should never be given intravenously. Insert the needle completely into either the left or right gluteus at a 90º angle to the skin.

Clinical studies have shown that the use of Sandostatin or Sandostatin LAR Depot may lead to heart problems in adults. These problems include sinus bradycardia, which is a type of slow heartbeat.

Do not discontinue the use of Sandostatin LAR without consulting your doctor, as your symptoms may return. If you have any concerns or inquiries regarding the usage of this medication, please consult your doctor, nurse, or pharmacist.

Carcinoid tumors, although cancerous, are often referred to as cancer in slow motion due to their ability to remain undetected for many years. However, in rare instances, when the tumor has metastasized, it can lead to the development of carcinoid syndrome, characterized by various symptoms.

Sandostatin LAR has been proven to effectively reduce elevated thyroid hormones, normalize TSH levels, and alleviate the clinical signs and symptoms of hyperthyroidism in patients with TSH-secreting adenomas. It is administered through a single intramuscular injection every 4 weeks.

Before starting treatment with Sandostatin LAR Depot, it is important to inform your doctor about any history of heart disease or if you are currently taking any other medications such as cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, or bromocriptine. It is also worth noting that the most frequently reported side effects of Sandostatin LAR Depot are back pain and fatigue.

The difference between Sandostatin LAR Depot and immediate-release Sandostatin Injection is that Sandostatin LAR Depot is a reformulation of immediate-release Sandostatin Injection. However, both formulations contain the same active ingredient, which is octreotide acetate.

You may experience nausea, vomiting, loose/oily stools, constipation, stomach upset, gas, bloating, dizziness, headache, pain, or irritation at the injection site. If any of these symptoms persist or worsen, please notify your doctor or pharmacist immediately.

Search savings options using NowPatient. Find out more about Sandostatin injection coupons, prices, and the NowPatient Rx Advantage savings card. This medication is available as a generic drug called octreotide. The average cost for 1 vial, 1mL of 50mcg/mL vials of octreotide is $19.89. However, you can purchase it at a discounted price of $11.28 by using the NowPatient Rx Advantage savings card, which will save you 43%.

Short-acting octreotide takes effect immediately, but its effects only last for a brief period. As a result, it requires more frequent injections, typically once or twice a day, to maintain its effectiveness.

People with carcinoid syndrome may experience frequent, watery stools along with abdominal cramps. They may also have difficulty breathing, with asthma-like signs such as wheezing and shortness of breath. These symptoms may occur simultaneously with skin flushing and a rapid heartbeat.

Octreotide can provide temporary relief by reducing the size of carcinoid tumors, but it is not a permanent cure. The initial form of octreotide, known as Sandostatin®, is administered through subcutaneous injections, typically at least twice a day. Some individuals are taught to self-administer these injections in the comfort of their own homes.

Octreotide acetate is a generic drug that is available as immediate-release Sandostatin. It is an identical replica of the active drug found in the brand-name medication.

The recommended initial dosage is 100-600 mcg/day subcutaneously, divided into 2-4 doses over the first 2 weeks. In clinical trials, the average daily maintenance dosage was approximately 450 mcg, but some patients experienced clinical and biochemical improvements with dosages ranging from 50-1,500 mcg/day. However, there is limited experience with dosages exceeding 750 mcg/day.

Sandostatin LAR Depot (octreotide acetate) is an injectable suspension for healthcare professionals.

For adults, the initial dosage is 20 milligrams (mg) injected into the buttocks once every 4 weeks for a period of 3 months. Your doctor will make any necessary adjustments to your dosage based on your individual needs and tolerance. As for children, the appropriate use and dosage should be determined by a doctor.

The immediate-release form of Sandostatin (octreotide acetate) can be administered either subcutaneously or intravenously using a needle. However, the most common method of administration is subcutaneous injection.

Sandostatin is not a form of chemotherapy; it is a synthetic hormone that mimics the effects of somatostatin, a hormone produced naturally in the body by the hypothalamus, pancreas, and gastrointestinal tract.

It can cause unexplained weight gain.

Out of the patients taking octreotide LAR, 7-21% experienced a decrease in body weight of 5% or more from their initial weight, which was not significantly different from the 11% observed in the placebo group. The most frequently reported side effects were diarrhea, headache, cholelithiasis, nausea, and abdominal pain.

Symptoms of low thyroid hormone levels include fatigue, feeling cold, depression, jaundice (yellowing of the skin and eyes), dark urine, skin rash and itching, and hair loss or thinning.

The 5-year relative survival rates for SEER stages are as follows:
– Localized: 97%
– Regional: 96%
– Distant: 68%
– All SEER stages combined: 94%

Quantity: 10
Unit Price: $140.02
Total Price: $1,400.18

If a carcinoid tumor is detected early, it can be completely removed through surgery. However, if the tumor is advanced at the time of discovery, complete removal may not be feasible. In such cases, surgeons may attempt to remove as much of the tumor as they can in order to manage the associated signs and symptoms.

Octreotide LAR or lanreotide is the recommended therapy for managing symptoms and inhibiting tumor growth over an extended period. This medication is administered once every month and is typically continued as long as it remains effective, potentially for the duration of one’s life.

Start treatment with Sandostatin Immediate-Release Injection and maintain it for a minimum of 2 weeks. The recommended daily dose varies from 100 mcg/d to 600 mcg/d, divided into 2 to 4 doses per day (average daily dose is 300 mcg/d) during the initial 2 weeks of therapy. Certain patients may need doses up to 1500 mcg/d.

You may experience nausea, vomiting, loose/oily stools, constipation, stomach upset, gas, bloating, dizziness, headache, pain, or irritation at the injection site. If any of these symptoms persist or worsen, please notify your doctor or pharmacist immediately.

The duration of Sandostatin’s action can vary, but it can last up to 12 hours depending on the type of tumor. Approximately 32% of the dose is eliminated unchanged through urine.

In the event of an Octreotide (Sandostatin) overdose, one may experience severe upper stomach pain, diarrhea, weight loss, warmth or tingling, numbness or cold feeling, unexplained muscle pain, weakness, weak pulse, fainting, or slow breathing (breathing may stop).

Octreotide Depot should only be given through deep intramuscular injection. The left and right gluteal muscles should be alternated for repeat injections (refer to section 6.6). If there is a hypersensitivity to the active ingredient or any of the listed excipients in section 6.1, the medication should not be used.